Latest data shows significant rise in parents sending kindergarteners to school without the required measles vaccine.

The FDA approved GSK's Penmenvy vaccine for ages 10-25, targeting five major meningococcal serogroups: A, B, C, W, and Y. Phase 3 trials with 4,800 participants showed the vaccine has a safety ...

Vaccines are a clinical product that is composed of live or dead material from an infectious agent – bacterium, virus, fungus or parasite – that elicit protective immunity against the pathogen ...

TUESDAY, Feb. 18, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive ...

These studies showed that the vaccine is effective, safe, and well-tolerated, with a safety profile similar to GSK’s licensed meningococcal vaccines, according to the news release by GSK.

The US Food and Drug Administration (FDA) has approved GSK's pentavalent meningococcal vaccine, Penmenvy, for children and young adults aged 10 to 25 years. This new vaccine provides protection ...

The FDA has approved Penmenvy, a vaccine for individuals aged 10 to 25, targeting five major serogroups of Neisseria meningitidis (A, B, C, W, and Y), which cause invasive meningococcal disease ...

The CDC’s Advisory Committee on Immunization Practices is expected to provide recommendations on the appropriate use of Penmenvy at its meeting on February 26, 2025. The Food and Drug ...

TUESDAY, Feb. 18, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for active immunization against invasive ...